3H-pyrazoloquinoline is an emerging and promising chemical scaffold capable of targeting the FLT3 receptor — one of the key molecular “switches” whose dysregulation drives the development of acute myeloid leukemia (AML). Among several dozen synthesized compounds, HSB401 stood out by strongly inhibiting the growth of leukemic cells, including those resistant to current therapies, and by slowing tumor progression in a mouse model. Importantly, it shows minimal effects on healthy blood cells, suggesting it could offer a gentler and safer alternative to existing AML treatments.
You can read the full article in Eur J Med Chem.